β-Blockers for the post-myocardial infarction patient: Current clinical evidence and practical considerations

Reviews in Cardiovascular Medicine

Volumn 7, Issue 1, 2006, Pages 1-9

  Fonarow, Gregg C ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

blockers; Left ventricular dysfunction; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; CARVEDILOL; CLOPIDOGREL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOTROPIC AGENT; ISOPRENALINE; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NITRATE; PLACEBO; PROPRANOLOL; SUCCINIC ACID; TIMOLOL;

ALGORITHM; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD CLOT LYSIS; BLOOD PRESSURE MONITORING; BRADYCARDIA; CARDIOGENIC SHOCK; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; EVIDENCE BASED MEDICINE; HEART BLOCK; HEART CATHETERIZATION; HEART FAILURE; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART REINFARCTION; HUMAN; HYPERKALEMIA; HYPOTENSION; INTERMETHOD COMPARISON; LONG TERM CARE; LOW DRUG DOSE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SMOKING CESSATION; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; SUDDEN DEATH; SURVIVAL RATE; SYMPTOMATOLOGY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADRENERGIC BETA-ANTAGONISTS; ALGORITHMS; ATENOLOL; CARBAZOLES; HUMANS; MYOCARDIAL INFARCTION; PRACTICE GUIDELINES; PROPANOLAMINES; PROPRANOLOL; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TIMOLOL;

EID: 33645781036     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. American Heart Association. Heart Disease and Stroke Statistics - 2006 Update. Dallas, TX: American Heart Association; 2006.
2. Crawford PA. The Washington Manual Cardiology Subspecialty Consult. Philadelphia: Lippincott Williams & Wilkins; 2003.
3. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110:588-636.
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Available at: http://www.acc.org/clinical/guidelines/unstable/unstable.pdf. Accessed January 6, 2005.
5. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 1998;260:2088-2093.
6. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333: 1670-1676.
7. Cleland JG, Torabi A, Khan NK. Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction. Heart. 2005;91(suppl 2):ii7-ii13.
8. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA. 1982;247:1707-1714.
9. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med. 1981;304:801-807.
10. CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357:1385-1390.
11. ISIS-1 Collaborative Group. Randomised trial of intravenous atenolol among 16, 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet. 1986;2:57-66.
12. Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Lopressor Intervention Trial Research Group. Eur Heart J. 1987;8:1056-1064.
13. Wu AH, Parsons L, Every NR, Bates ER. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol. 2002;40: 1389-1394.
14. Hasdai D, Topol EJ, Kilaru R, et al. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. Am Heart J. 2003;145:73-79.
15. Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004; 109:494-499.
16. Wang TJ, Levy D, Benjamin EJ, Vasan RS. The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening. Ann Intern Med. 2003;138:907-916.
17. Weir R, McMurray JJ. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction. Heart. 2005; 91(suppl 2):ii17-ii20.
18. Fonarow GC, Abraham WT, Cannon CP, et al. Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction. Rev Cardiovasc Med. 2003;4(Suppl 3):S54-S59.
19. Hjalmarson A, Herlitz J, Holmberg S, et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation. 1983;67:126-132.
20. MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The MIAMI Trial Research Group. Eur Heart J. 1985;6:199-226.
21. Freemantle N, Cleland J, Young P, et al. Beta-blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ. 1999;318:1730-1737.
22. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation. 1991;83:422-437.
23. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366: 1622-1632.
24. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA. 1983;250:2814-2819.
25. COREG (carvedilol) tablets [prescribing information]. Research Triangle Park, NC: Glaxo-SmithKline; 2005.
26. Lopez-Sendon Hentsch J, Dargie H, Remme W, et al. Effect of carvedilol on mortality and reinfarction in left ventricular dysfunction after infarction. A subgroup analysis from the CAPRICORN study [abstract 2081]. Eur Heart J. 2002;4:396.
27. GlaxoSmithKline. Data on file. Research Triangle Park, NC: GlaxoSmithKline, 2005.
28. Doughty RN, Whalley GA, Walsh HA, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation. 2004; 109:201-206.
29. Fonarow GC. Practical considerations of beta-blockade in the management of the post-myocardial infarction patient. Am Heart J. 2005;149:984-993.
30. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94:2807-2816.
31. Willenheimer R, van Veldhuisen DJ, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112: 2426-2435.
32. Sliwa K, Norton GR, Kone N, et al. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol. 2004;44:182S-1830.
33. Sackner-Bernstein JD. New evidence from the CAPRICORN trial: the role of carvedilol in high-risk, post-myocardial infarction patients. Rev Cardiovasc Med. 2003;4(suppl 3):S25-S29.